US Patent Issued to NADIANBIO on March 25 for "Composition comprising naphthoquinone-based compound as active ingredient, for preventing or ameliorating fatigue, cachexia, pain, cognitive decline and hematopoietic stem cell reduction which are side effects related to anticancer drug treatment" (South Korean Inventors)

ALEXANDRIA, Va., March 26 -- United States Patent no. 12,257,230, issued on March 25, was assigned to NADIANBIO Ltd. (Iksan-si, South Korea).

"Composition comprising naphthoquinone-based compound as active ingredient, for preventing or ameliorating fatigue, cachexia, pain, cognitive decline and hematopoietic stem cell reduction which are side effects related to anticancer drug treatment" was invented by Hong Seob So (Iksan-si, South Korea), Hyung-Jin Kim (Iksan-si, South Korea), Gi-Su Oh (Iksan-si, South Korea), Seunghoon Lee (Iksan-si, South Korea) and Dipendra Khadka (Iksan-si, South Korea).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to a composition comprising a naphthoquin...